Monitoring Response to Radioligand Therapy in Prostate Cancer
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
How Will Indolent Lymphoma/B-Cell NHL Care Be Improved in the Future?
There will be an unmet need for therapy in patients with aggressive lymphomas who did not benefit from therapy with bispecifics, CAR-T, chemotherapy, and targeted therapy.
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.
How to Optimize Quality of Life During Thoracic Radiotherapy for LS-SCLC?
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
Tarlatamab Requires Strategic Toxicity Monitoring and Management in ES-SCLC
A real-world, retrospective analysis showed that CRS and ICANS occurred in 48% and 16% of patients with ES-SCLC who were treated with tarlatamab.
Trastuzumab Deruxtecan Regimen Accepted for Review in HER2+ Breast Cancer
The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast cancer population.
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
Combination therapy of ETX-636 plus fulvestrant is being administered to patients with HR–positive, HER2-negative breast cancer in a phase 1/2 trial.
Refining Artificial Intelligence Tools in Cancer Pathology and Research
David Rimm, MD, PhD, discussed how AI tools may help automate routine tasks for pathologists and predict genomic alterations from images.
Tarlatamab May Offer New SOC for Relapsed ES-SCLC With Brain Metastases
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Fitting Radioligands Into the Metastatic Prostate Cancer Treatment Paradigm
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
SC Mosunetuzumab Will Be Accessible for MZL Care in Community Settings
The subcutaneous formulation of mosunetuzumab will require 17 cycles of therapy, without any maintenance, and can be done in outpatient settings.
Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?
D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.
Twice-Daily Chemoradiotherapy Boosts Survival in Limited-Stage SCLC
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
FDA Receives BLA for Pivekimab Sunirine in Rare Hematologic Malignancy
Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.
FDA Grants Fast Track Designation to UB-VV111 in Select B-Cell Malignancies
A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.
Companion Diagnostic Earns FDA Approval for Imlunestrant in Breast Cancer
In the phase 3 EMBER-3 trial, Guardant360 CDx was used to identify patients with ESR1-mutated advanced breast cancer who may benefit from imlunestrant.
What AEs Should Physicians Be Aware of With Bispecifics in Indolent Lymphoma?
Respiratory, viral, and bacterial infections have emerged as a toxicity of note during bispecific antibody treatment for indolent lymphoma.
Advancing AI in Pathology, Precision Medicine, and the Melanoma Landscape
David Rimm, MD, PhD, shared the rationale behind developing an AI-driven tool for quantifying tumor-infiltrating lymphocytes in melanoma.
Moving Beyond Chemotherapy in Relapsed/Refractory ES-SCLC Treatment
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer
The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.
Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC
Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.
Older matched sibling donor versus young haplo-identical donor for elderly patients with acute myeloid leukemia
Researchers conducted a large registry-based analysis comparing haploidentical donors and older matched sibling donors in older patients with AML.
SBRT Reduces Bowel Toxicity vs IMRT in Intermediate-Risk Prostate Cancer
SBRT achieved a 5-year DFS of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate risk prostate cancer.
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
Why do some patients with follicular lymphoma experience benefit from axi-cel while others relapse or develop severe toxicities?
Data Favor Twice-Daily vs Once-Daily Chemoradiotherapy in LS-SCLC
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC
Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.
Anito-cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma
Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.
TTFields After SRS Prolongs Intracranial Response in Brain Metastatic NSCLC
The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.
FDA Advises Against BLA for Novel Vaccine Combo/Pembrolizumab in Melanoma
Adjuvanted imsapepimut and etimupepimut plus pembrolizumab did not yield a statistically significant PFS improvement as treatment for advanced melanoma.
Biomarker Expression Intensity Impacts Melanoma Treatment Decision-Making
The development of multimodal biomarkers may help predict response to immunotherapy among patients with melanoma and other malignancies.
